The patent claims are directed to the composition of matter and methods of use, including inhibiting tissue damage caused by ultraviolet radiation and promoting neurite outgrowth and neuron
The company’s latest report* states that Stelara, an IL12/IL23 inhibitor, has demonstrated a strong safety profile in other indications, and is expected to launch in the US and
Lysogene and Alcyone Lifesciences will join forces to evaluate the intraparenchymal delivery of Lysogene’s proprietary rAAV to treat patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as
Simulations Plus will continue to provide licenses for its GastroPlus, ADMET Predictor, and MedChem Studio software programs for use by the DNTP/NIEHS. The DNTP within the NIEHS is
Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove LDL-C, or "bad" cholesterol, from the blood. Elevated LDL-C is
The study findings, which are being presented in a late-breaking oral presentation at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, confirmed the antiretroviral
Neither the R&D goal that generated the milestone payment nor the amount were disclosed. The MvfR inhibitor program targets mechanisms of virulence and persistence in Pseudomonas and other
Dex-IN met the primary endpoint of the clinical trial in demonstrating significant pain relief compared with placebo over 48 hours. The Company plans to meet with the FDA
The Phase 1/2 results were previously announced in November 2014. Yotam Nisemblat, BioLineRx Drug Development Director, will present the data in a talk titled BL-7010, a Novel Potential
This patent, entitled "Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria," contains composition claims for the CF-301 sequence and variants having at least 80% identity.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.